Scientific American reports on Population Council’s upcoming international clinical trial of a Nestorone®/Testosterone gel, a novel reversible contraceptive for men.
While men currently have very few options for safe and reversible methods of contraception, research and development of such products has faced an array of challenges. Scientific American looks at a novel prospective contraceptive gel developed by the Council in partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, which is slated to enter additional Phase 2 clinical trials to assess efficacy, as well as safety and acceptability of the gel.
The investigational gel is designed to be applied once daily and absorbed through the skin of a man’s shoulders and upper arms. Initial clinical studies indicate that the use of the Nestorone®/Testosterone gel reduced sperm production while maintaining healthy testosterone levels, thereby minimizing side effects such as lower libido, acne, weight gain, and altered cholesterol levels.
“The project, led by the U.S. National Institutes of Health and the Population Council, is expected to begin signing up couples in early 2018, along with collaborating partners at nine locations in the U.K., Sweden, Italy, Chile, Kenya and several medical centers in the U.S. Once these sites get institutional and national review board sign-offs, the study will test whether the latest version of a hormonal birth control system for men can overcome the myriad obstacles that have sidelined earlier efforts.”
Read more at Scientific American.